Epilepsy Market Size (7MM) was valued at ~$9B in 2023, growing at a 7% CAGR through 2034.

The Epilepsy Market Size in the 7MM was ~USD 9 billion in 2023 and is projected to increase during the forecast period (2024–2034), with a CAGR of approximately 7%. DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Epilepsy Market Landscape. By analyzing historical data, current Epilepsy Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Epilepsy, historical and forecasted epidemiology, as well as the Epilepsy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover more about the epilepsy market in detail @ Epilepsy Market Report

Key Takeaways from the Epilepsy Market Report

• In the 7MM, the total Epilepsy diagnosed prevalent cases were nearly 7 million in 2023, which is expected to increase at a CAGR of 0.4% by 2034.
• In the US, the total diagnosed epilepsy prevalence cases were approximately 3.3 million in 2023, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2034.
• In 2023, the diagnosed prevalent cases in the EU4 and the UK comprised nearly 1.3 million male cases and 1.5 million female cases. These numbers are expected to rise throughout the study period.
• In 2023, among EU4 and the UK, Germany had the highest number of cases of epilepsy, i.e., 735 thousand, of which nearly 74% of the cases were focal epileptic seizures, 18% were generalized epileptic seizures, while 8% of the cases were other determined or undetermined epileptic seizures.
• Among the 7MM, in 2023, Japan accounted for the second highest diagnosed prevalent cases of epilepsy, i.e., 890 thousand cases, these cases are expected to change during the study period.
• In Japan, among the other types of epilepsies and associated diseases, the highest cases were found in drug-resistant epilepsy/refractory cases, i.e., 82 thousand followed by photosensitivity and childhood absence epilepsy with equal cases, i.e., 44 thousand, in 2023. These cases are expected to change by 2034.
• The leading Epilepsy Companies such as Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
• Promising Epilepsy Therapies such as XEN1101, Soticlestat (TAK-935), BHV-7000 (KB-3061), PRAX-562, STACCATO alprazolam (benzodiazepine) and others.

Get a Free sample for the Epilepsy Market Report @ Epilepsy Therapeutics Market

Epilepsy Overview

Epilepsy is a long-term neurological disorder that affects individuals of all ages, leading to recurrent and unprovoked seizures. These seizures result from sudden, uncontrolled electrical disturbances in the brain, which can cause convulsions, altered consciousness, or unusual sensations and behaviors.

Epilepsy Epidemiology Segmentation in the 7MM

• Total Epilepsy Diagnosed Prevalent Cases
• Epilepsy Gender-specific Diagnosed Prevalent Cases
• Epilepsy Diagnosed Prevalent Cases Based on Seizure Type
• Diagnosed Cases of Other Types of Epilepsies and Associated Diseases

Download the report to understand which factors are driving Axillary Hyperhidrosis epidemiology trends @ Axillary Hyperhidrosis Prevalence

Epilepsy Marketed Drugs

·        LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

LIBERVANT is a buccally, or inside of the cheek, administered film formulation of diazepam, a benzodiazepine intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older. The drug has been developed as an alternative to the device-based products currently available for patients with refractory epilepsy, including rectal gel and nasal spray products. The company has utilized PharmFilm technology to develop a diazepam formulation that is absorbed directly through the buccal mucosa. The buccal mucosa’s wide, relatively immobile, and highly permeable surface area provided the stable and controlled microenvironment needed to optimize adhesion, absorption, and onset of action.

·        EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals

EPIDIOLEX/EPIDYOLEX (cannabidiol), an oral solution, is a clear, colorless-to-yellow liquid containing cannabidiol at 100 mg/mL concentration. Cannabidiol, the active ingredient in EPIDIOLEX, is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. Inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. EPIDIOLEX contains no ingredient made from a gluten-containing grain (wheat, barley, or rye). The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. EPIDIOLEX is approved for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Jazz Pharmaceuticals had initiated a Phase III trial to treat children and adolescents living with developmental and epileptic encephalopathy, however, the trial was terminated due to a business decision. The Japanese unit of Jazz Pharmaceuticals has started a trial of the drug for epilepsy in Japan.

·        XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical

Cenobamate is a novel antiseizure medication discovered and developed by SK Biopharmaceuticals and SK Life Science. While the precise mechanism by which cenobamate moa exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the ion channel ?-aminobutyric acid (GABA-A). Cenobamate is approved in the US for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI (cenobamate tablets). It can be combined with other ASMs or used alone.

·        AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

AFINITOR DISPERZ/VOTUBIA is an oral inhibitor of the mammalian target of the rapamycin (mTOR) pathway. AFINITOR DISPERZ is the first adjunctive treatment approved in the US, specifically for adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. The product is also approved in more than 30 countries, including EU member states, for treating TSC-associated seizures. AFINITOR works by inhibiting the mammalian target of rapamycin (mTOR), a protein that regulates multiple cellular functions. Treatment with an mTOR inhibitor in animal models of mTOR dysregulation in the brain resulted in prolonged survival, seizure suppression, prevention of the development of new-onset seizures, and prevention of premature death. Additionally, the drug is approved for other indications, including TSC with subependymal giant cell astrocytoma (SEGA). The recommended starting dosage of AFINITOR DISPERZ (everolimus tablets for oral suspension) is 5 mg/m2 orally once daily until disease progression or unacceptable toxicity.

Epilepsy Emerging Drugs

·        XEN1101/Azetukalner: Xenon Pharmaceuticals

XEN1101 is a novel, orally administered, potent, selective KCNQ2/3 (Kv7.2/7.3) potassium channel opener being developed to treat focal onset seizures and primary generalized tonic-clonic seizures (PGTCS). It acts as a neuronal Kv7 voltage-gated potassium channel opener and has been developed to stabilize nerve cells, control action potential burst firing, and reduce brain hyperexcitability as a seizure treatment. The Kv7 potassium channel mechanism has been clinically validated with ezogabine. The FDA approved this earlier generation Kv7 modulator as an adjunctive treatment for adults with focal seizures with or without secondary generalization. XEN1101’s unique composition is chemically designed to improve the potency, selectivity, and pharmacokinetics of ezogabine and is not expected to have ezogabine’s composition-specific tissue pigmentation effects. The drug is currently being investigated in multiple Phase III clinical trials to treat patients with focal-onset and primary generalized tonic-clonic seizures with topline data anticipated in the second half of 2025. Moreover, the drug is also being developed for major depressive disorder and is undergoing Phase II clinical trials.

·        Soticlestat (TAK-935): Takeda/Ovid Therapeutics

Soticlestat (TAK-935), formerly known as OV935, is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). CH24H is predominantly expressed in the brain and plays a central role in cholesterol homeostasis. CH24H converts cholesterol to 24-S-hydroxycholesterol (24HC), exiting the brain into the blood plasma circulation. It is believed that CH24H is involved in the over-activation of the glutamatergic pathway, which has been shown to play a role in the initiation and spread of seizure activity. TAK-935 is the only molecule with this mechanism of action in clinical development. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve the excitatory/inhibitory balance in the brain, thereby reducing seizure susceptibility and improving seizure control. Recently the company posted topline results for soticlestat (TAK-935) in patients with dravet syndrome and lennox-gastaut syndrome. Soticlestat showed a consistent and favorable safety and tolerability profile in the studies. Furthermore the company will move forward to discuss the totality of the data with regulatory authorities.

·        BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences

BHV-7000 is a potent, selective activator of Kv7.2/7.3 potassium channels, a clinically validated target to regulate the hyperexcitable state in epilepsy. BHV-7000 is structurally and pharmacologically distinct from other potassium channel activators and demonstrates minimal GABAA receptor activation, potentially providing better tolerability. BHV-7000 was potent in the maximal electroshock (MES) preclinical epilepsy model without adverse effects on neurobehavior and was well-tolerated in a Phase I SAD/MAD clinical study without CNS adverse events typical of antiseizure medications. Currently, Phase II/III studies in focal epilepsy are ongoing. Moreover, the company is also enrolling participants in ongoing pivotal clinical trials with the Kv7 activator, BHV-7000, targeting generalized epilepsy, bipolar disorder, and major depressive disorder.

Discover more about therapies set to grab major Epilepsy Market Share @ Epilepsy Market Drivers and Barriers

Epilepsy Drugs Market Insights

Epilepsy treatment involves various drug classes to control seizures, including sodium channel blockers (e.g., phenytoin, lamotrigine), which stabilize neuronal activity by inhibiting abnormal electrical impulses. Calcium channel blockers (e.g., ethosuximide) are effective for absence seizures, while GABAergic agents (e.g., valproate, benzodiazepines) enhance inhibitory neurotransmission to reduce seizure frequency. Newer-generation AEDs like levetiracetam and topiramate offer broader efficacy with fewer side effects, addressing both generalized and focal seizures. Non-pharmacological options such as vagus nerve stimulation (VNS) and the ketogenic diet are also utilized, particularly in drug-resistant cases, providing additional therapeutic avenues.

Major Epilepsy Companies

Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.

Scope of the Epilepsy Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period- 2024-2034
• Epilepsy Companies- Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others
• Epilepsy Therapies- XEN1101, Soticlestat (TAK-935), BHV-7000 (KB-3061), PRAX-562, STACCATO alprazolam (benzodiazepine) and others.
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy Emerging Therapies
• Epilepsy Market Dynamics: Epilepsy Market Drivers and Epilepsy Market Barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Epilepsy Unmet Needs, KOL's views, Analyst's views, Epilepsy Market Access and Reimbursement

To know more about Epilepsy Companies working in the treatment market, visit @ Epilepsy Market Access and Reimbursement

Table of Contents

1 Key Insights

2 Report Introduction

3 Epilepsy Market Overview at a Glance

4 Methodology of Epilepsy Epidemiology and Market

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Epilepsy Patient Journey

9 Epilepsy Epidemiology and Patient Population

10 Epilepsy Marketed Drugs

11 Epilepsy Emerging Drugs

12 Epilepsy: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Epilepsy Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.